Author: Tatjana Anderer

Munich, Germany — Equis­tone Part­ners Europe (“Equis­tone”), one of Europe’s most active equity inves­tors, has acqui­red a majo­rity stake in Omni­care, a Germany-wide phar­maceu­ti­cal whole­sa­ler focu­sed on the distri­bu­tion of finis­hed dosage forms for the pati­ent-speci­fic produc­tion of cancer drugs. The seller of the shares is the current consor­tium of share­hol­ders, which reta­ins a signi­fi­cant stake. — The manage­ment team around Mana­ging Direc­tor Oliver Tamimi will conti­nue to be respon­si­ble for the company and will make a signi­fi­cant invest­ment in the course of the tran­sac­tion. The parties have agreed not to disc­lose details of the tran­sac­tion. The acqui­si­tion is still subject to appr­oval by the rele­vant anti­trust autho­ri­ties. The tran­sac­tion is expec­ted to close in the fourth quar­ter of 2019.

Omni­care was foun­ded in 2002 as a phar­maceu­ti­cal specialty whole­sa­ler for outpa­ti­ent onco­logy care in Germany. To date, the company has become the market leader for the distri­bu­tion of finis­hed onco­logy drugs requi­red by phar­macies for pati­ent-speci­fic infu­si­ons. In addi­tion to the supply of finis­hed phar­maceu­ti­cals, Omni­care has been deve­lo­ping important services for highly specia­li­zed phar­macies and medi­cal prac­ti­ces since 2012 for quality assu­rance, clean­room hygiene moni­to­ring, and the trai­ning and conti­nuing educa­tion of specia­list staff. In early 2019, these services were expan­ded to become the Omni­care Quality Initia­tive, with the goal of provi­ding safe, high-quality care to onco­logy patients.

In 2018, Omni­care also estab­lished the “German Onco­logy Network” of leading onco­logy prac­ti­ces and has been conti­nuously expan­ding it ever since. The goal of this network is the struc­tu­ral streng­thening and further deve­lo­p­ment of onco­logy prac­ti­ces for the bene­fit of pati­ents. Omni­care has syste­ma­ti­cally deve­lo­ped into a leading plat­form for outpa­ti­ent onco­logy care in Germany. In this way, the company is making a signi­fi­cant contri­bu­tion to provi­ding the best possi­ble care for cancer pati­ents close to home in Germany. Omni­care gene­ra­tes annual sales of appro­xi­m­ately 670 million euros and employs 193 people in Unter­föh­ring, Colo­gne and Calw. In 2019, Omni­care is expec­ted to achieve sales growth of around 5 percent.

Dirk Sche­kerka (photo), Senior Part­ner and Coun­try Head DACH at Equis­tone, says: “Omnicare’s busi­ness model aims to contri­bute to the secu­rity of care and the highest quality of therapy for cancer pati­ents close to home. We are plea­sed to part­ner with the company in this endea­vor.” Alexis Milko­vic, Part­ner at Equis­tone, adds: “Omni­care has a strong market posi­tion, an expe­ri­en­ced manage­ment team and excel­lent employees. These are excel­lent prere­qui­si­tes for the further deve­lo­p­ment of the company. As a new share­hol­der, we want to support Omni­care in further streng­thening and sustain­ably expan­ding its position.”

Oliver Tamimi, Mana­ging Direc­tor at Omni­care, says: “With Equis­tone, we have found a relia­ble and well-funded new part­ner for the further deve­lo­p­ment of our company. With Equistone’s support, we want to conti­nuously improve the care of cancer pati­ents in Germany close to their homes and on an outpa­ti­ent basis.”

On the Equis­tone side, Dirk Sche­kerka, Alexis Milko­vic and Julia Bruns­wi­cker are respon­si­ble for the transaction.

Advi­sor Equistone: 
P+P (Legal & Tax), Alva­rez & Marsal (Commer­cial), Deloitte (Finan­cial), Houli­han Lokey (Finan­cing), Dechert (Anti­trust), Shear­man & Ster­ling (Legal Finan­cing) and ETS (Insu­rance).

On Omnicare’s side, Henge­ler Müller (Legal and Anti­trust), BCG (Commer­cial), KPMG (Finan­cial), EY (Tax), Lincoln Inter­na­tio­nal (M&A) and Honert & Part­ner (MEP) advi­sed the manage­ment team on the transaction.

About Omni­care
Omni­care was foun­ded in 2002 as a phar­maceu­ti­cal whole­sa­ler supp­ly­ing specia­li­zed phar­macies throug­hout Germany. Since 2012, it has been working as a coope­ra­tive of cyto­sta­tics manu­fac­tu­ring phar­macies to preserve and secure the future of outpa­ti­ent onco­logy in Germany. The Omni­care Quality Initia­tive enables phar­macies to safely and effi­ci­ently provide onco­logy prac­ti­ces and their pati­ents with essen­tial medi­ca­ti­ons for survi­val. With the German Onco­logy Network, Omni­care has laun­ched a plat­form of leading onco­logy prac­ti­ces to streng­then outpa­ti­ent pati­ent care. In addi­tion, the company offers prac­tice-rele­vant trai­ning for prac­ti­ces and phar­macies and provi­des soft­ware solu­ti­ons that enable effi­ci­ent and safe chemo­the­rapy plan­ning and ordering.

About Equis­tone Part­ners Europe
Equis­tone Part­ners Europe is one of Europe’s leading equity inves­tors with a team of more than 40 invest­ment specia­lists in six offices in Germany, Switz­er­land, the Nether­lands, France and the UK. Equis­tone prima­rily invests in estab­lished medium-sized compa­nies with a good market posi­tion, above-average growth poten­tial and an enter­prise value of between EUR 50 and 500 million. Since its foun­ding, equity has been inves­ted in more than 140 tran­sac­tions, mainly mid-market buy-outs. The port­fo­lio curr­ently compri­ses over 40 compa­nies across Europe, inclu­ding around 20 active holdings in Germany, Switz­er­land and the Nether­lands. Equis­tone is curr­ently inves­t­ing from its sixth fund, which closed in March 2018 with €2.8 billion at the hard cap.

Frank­furt am Main — Deut­sche Betei­li­gungs AG (DBAG) closes the first nine months of finan­cial year 2018/2019 with conso­li­da­ted earnings of 12.6 million euros. The reason for the signi­fi­cant decline compared to the corre­spon­ding period of the previous year, when conso­li­da­ted net income amoun­ted to 27.7 million euros, is the lower result from the invest­ment busi­ness: A lower valua­tion result could not be fully compen­sa­ted by posi­tive earnings contri­bu­ti­ons from disposals.

In its 2018/2019 half-year report, DBAG had repor­ted that most port­fo­lio compa­nies had budgeted for higher reve­nues and earnings in 2019 and conside­red them­sel­ves to be on a good track. This has not chan­ged in prin­ci­ple. In the mean­time, howe­ver, there have been incre­asing signs of a slow­down in econo­mic momen­tum — partly due to the simme­ring global trade conflicts. This leads to lower than expec­ted earnings at some port­fo­lio compa­nies and thus has a nega­tive impact on the valua­tion of the port­fo­lio compa­nies and earnings from the invest­ment busi­ness. In the third quar­ter of the current fiscal year in parti­cu­lar, there was also a nega­tive earnings contri­bu­tion from the change in the debt of the port­fo­lio compa­nies. In the case of one port­fo­lio company, for exam­ple, the finan­cing of an acqui­si­tion had impac­ted its leverage ratio and subse­quently its valuation.

Howe­ver, the fact that DBAG’s port­fo­lio is diver­si­fied is paying off. “The econo­mic slow­down in various sectors contrasts with posi­tive deve­lo­p­ments at port­fo­lio compa­nies in other sectors. For exam­ple, invest­ments in the tele­com­mu­ni­ca­ti­ons sector with a focus on fast inter­net have recently deve­lo­ped very posi­tively,” states DBAG’s quar­terly state­ment published today. On balance, the opera­ting perfor­mance of the port­fo­lio compa­nies, i.e. the change in earnings and debt, contri­bu­ted 6.2 million euros to earnings in the first nine months, compared with 13.3 million euros in the corre­spon­ding prior-year period.

The dispo­sals of the share­hol­dings in Infiana and Novo­press, which were agreed after the report­ing date, made a posi­tive contri­bu­tion of 13.7 million euros to the conso­li­da­ted result. In both cases, the proceeds from the sale excee­ded the carry­ing amount of the invest­ments as of March 31, 2019. The corre­spon­ding value contri­bu­ti­ons were included in the valua­tion of the two invest­ments as of June 30, 2019. “The recently announ­ced dispo­sals once again under­line the success of our invest­ment acti­vi­ties,” commen­ted Susanne Zeid­ler, CFO of DBAG, in connec­tion with the publi­ca­tion of the quar­terly finan­cial state­ments. And he conti­nues: “In both cases, we have multi­plied the capi­tal inves­ted. Our success is ther­e­fore not reflec­ted in the valua­tion result of a single quar­ter, but is only deter­mi­ned after seve­ral years, when we sell an invest­ment again.”

At the begin­ning of the current finan­cial year, the partly massive decline in the earnings multi­ples of listed peer compa­nies, which DBAG uses to value its port­fo­lio compa­nies, had a strong impact on conso­li­da­ted earnings. Follo­wing a signi­fi­cant reco­very in valua­tion multi­ples in the second and third quar­ters, this capi­tal market effect was again almost neutral as of June 30, 2019.

Earnings before taxes in the Private Equity Invest­ments segment reached 11.0 million euros after the first nine months of the finan­cial year, down 12.5 million euros on the segment result for the same period of the previous year. This was due to signi­fi­cantly lower earnings from the invest­ment busi­ness. The fund consul­ting segment perfor­med worse than plan­ned, with earnings before taxes of 1.6 million euros, compared with 4.2 million euros in the corre­spon­ding prior-year period. As expec­ted, income from manage­ment and advi­sory services for DBAG Fund VI, DBAG Fund V and DBAG ECF decli­ned. Howe­ver, there were also unplan­ned expen­ses, higher expen­ses for uncom­ple­ted tran­sac­tions and higher person­nel expen­ses due to varia­ble compen­sa­tion for DBAG employees follo­wing successful dispo­sals and new invest­ments. Conso­li­da­ted net income of 12.6 million euros resul­ted in a return on equity of 3.1 percent in the first nine months.

In view of incre­asing macroe­co­no­mic uncer­tain­ties, DBAG redu­ced its fore­cast for the current fiscal year on July 10, 2019. Assum­ing stable valua­tion condi­ti­ons on the capi­tal market, it expects conso­li­da­ted earnings for the 2018/2019 finan­cial year to be at least positive.

DBAG contin­ued to invest along­side DBAG Fund VII in the third quar­ter of 2018/2019. The MBO of IT services company Cloudf­light was the fund’s seventh invest­ment. With the fulfill­ment of the legal requi­re­ments, the invest­ment in the radio­logy group blikk was also comple­ted in the third quar­ter. This means that around 65 percent of the invest­ment commit­ments of DBAG Fund VII, which has been inves­t­ing in medium-sized compa­nies since Decem­ber 2016, are commit­ted. “That is why we remain confi­dent about the future,” affirmed CFO Susanne Zeid­ler. “With these invest­ments, we have laid the foun­da­tion for future success.”

About DBAG
Deut­sche Betei­li­gungs AG, a listed company, initia­tes closed-end private equity funds and invests along­side DBAG funds in well-posi­tio­ned medium-sized compa­nies with deve­lo­p­ment poten­tial. DBAG focu­ses on indus­trial sectors in which German SMEs are parti­cu­larly strong by inter­na­tio­nal stan­dards. With this expe­ri­ence, know-how and equity, it streng­thens the port­fo­lio compa­nies in imple­men­ting a long-term, value-enhan­cing corpo­rate stra­tegy. The entre­pre­neu­rial invest­ment approach makes DBAG a sought-after invest­ment part­ner in the German-spea­king region. The capi­tal mana­ged and advi­sed by the DBAG Group amounts to appro­xi­m­ately 1.7 billion euros.

Frank­furt a. Main — The IK Invest­ment Part­ners advi­sed fund comple­tes acqui­si­tion of LAP GmbH Laser Appli­ca­ti­ons from thePri­vate Equity company Capi­ton AG. LAP, based in Lüne­burg, Germany, is a leading supplier of laser posi­tio­ning systems as well as soft­ware and hard­ware for quality assu­rance in radia­tion therapy. — Inter­na­tio­nal law firm Clif­ford Chance has advi­sed a consor­tium of banks on the finan­cing of the acqui­si­tion of LAP GmbH Laser Appli­ca­ti­ons by funds advi­sed by IK Invest­ment Partners.

The banking syndi­cate finan­cing the acqui­si­tion includes Commerz­bank AG, Deut­sche Apothe­ker- und Ärzte­bank eG, Hermes Direct Lending, Idin­vest Part­ners S.A., Raiff­ei­sen Bank Inter­na­tio­nal AG, Siemens Bank GmbH as well as SEB AB Frank­furt Branch and COMMERZBANK Finance & Covered Bond S.A. as agent and secu­rity agent.

About IK Invest­ment Partners
IK Invest­ment Part­ners is a Euro­pean private equity advi­sory group with Nordic roots, opera­ting across Nort­hern Conti­nen­tal Europe. Focu­sed on inves­t­ing in compa­nies with strong under­ly­ing poten­tial, we are proud to support the IK Funds as they part­ner with manage­ment teams and inves­tors to grow busi­nesses, improve perfor­mance and create sustainable value for all our stakeholders.

Deeply commit­ted to foste­ring growth, we apply an active approach to our invest­ments and aim to create robust, well posi­tio­ned compa­nies with excel­lent long-term pros­pects. Foun­ded in 1989, we have helped over 125 compa­nies expand and deve­lop sustain­ably. We strive constantly to make a diffe­rence to our port­fo­lio compa­nies, our inves­tors and to society.

About Clif­ford Chance
The inter­na­tio­nal Clif­ford Chance team was led by part­ner Stef­fen Schell­schmidt (Banking & Capi­tal Markets, Frankfurt).
Clif­ford Chance, one of the world’s leading law firms, is present for its clients with around 3,400 legal advi­sors in all major busi­ness centers around the world. In Germany, Clif­ford Chance is repre­sen­ted by around 300 lawy­ers, audi­tors, tax advi­sors and soli­ci­tors in Düssel­dorf, Frank­furt am Main and Munich.

Munich/ Frank­furt a. Main — The Munich and Frank­furt offices of the inter­na­tio­nal law firm Weil, Gotshal & Manges LLP have advi­sed KKR on the acqui­si­tion of a majo­rity stake for more than €600 million in the German FinTech company heidel­pay (Heidel­ber­ger Payment GmbH) from AnaCap Finan­cial Part­ners. The closing of the tran­sac­tion is subject to the appr­oval of BaFin and other regu­la­tory autho­ri­ties as well as custo­mary closing condi­ti­ons. The parties have agreed not to disc­lose the purchase price.

Foun­ded in 2003 and based in Heidel­berg, the heidel­pay Group is one of the fastest growing full-service provi­ders of elec­tro­nic payment services in Europe.

The Weil team was led in this tran­sac­tion by Frank­furt-based Corpo­rate Part­ner Prof. Dr. Gerhard Schmidt (photo). and compri­sed the part­ners Tobias Geer­ling (Tax, Munich), Dr. Barbara Jagers­ber­ger (Corpo­rate, Munich) and Dr. Uwe Hart­mann (Regu­la­tory, Frank­furt) as well as the asso­cia­tes Manuel-Peter Fringer, Alex­an­der Pfef­fer­ler, Andreas Fogel (all Corpo­rate, Munich), Dr. Ansgar Wimber, Florian Wessel (both Corpo­rate, Frank­furt), Benja­min Rapp (Tax, Munich), Mareike Pfeif­fer (Labor Law, Frank­furt), Svenja Wach­tel (Liti­ga­tion, Munich), Dr. Konstan­tin Hoppe, Dr. Barbara Sand­fuchs (both IT/IP, Munich) and Para­le­gal Madleen Düdder (Corpo­rate, Munich).

About Weil, Gotshal & Manges 
Weil, Gotshal & Manges is an inter­na­tio­nal law firm with more than 1,100 lawy­ers, inclu­ding appro­xi­m­ately 300 part­ners. Weil is head­quar­te­red in New York and has offices in Boston, Dallas, Frank­furt, Hong Kong, Hous­ton, London, Miami, Munich, Paris, Beijing, Prince­ton, Shang­hai, Sili­con Valley, Warsaw and Washing­ton, D.C. www.weil.com

Frank­furt / Wies­ba­den (Germany), Tokyo (Japan) — From Triton (“Triton”) advi­sed funds have comple­ted the sale of COBEX, a leading manu­fac­tu­rer and supplier of carbon and graphite products for alumi­num, primary iron and iron and other smel­ting indus­tries, to TokaiCarbon Co, Ltd (“Tokai Carbon”), a pioneer in the Japa­nese carbon products indus­try, for an enter­prise value of EUR 825 million.

Triton acqui­red COBEX, SGL Group’s former catho­des, furnace linings and carbon elec­tro­des busi­ness, in 2017. About Cobex­COBEX is a leading global manu­fac­tu­rer of carbon and graphite products for the primary alumi­num and iron indus­tries and other metall­ur­gi­cal smel­ting proces­ses. COBEX’s core compe­ten­cies lie in the produc­tion of premium quality catho­des, furnace linings and carbon elec­tro­des with maxi­mum consis­tency. COBEX main­ta­ins long-stan­ding, trus­ting part­ner­ships with nume­rous custo­mers around the world.

With inno­va­tive solu­ti­ons COBEX helps its custo­mers to create added value and opti­mize total cost of owner­ship. A highly quali­fied team with many years of expe­ri­ence in product deve­lo­p­ment and appli­ca­tion supports custo­mers with tech­ni­cal know­ledge and skills. COBEX is based in Wies­ba­den, Germany. The company also has two plants in Poland and sales and tech­ni­cal services in China. https://cobexgroup.com

About Tokai Carbon
Tokai Carbon was foun­ded in 1918 and has been a market leader for over 100 years in manu­fac­tu­ring and distri­bu­ting a wide range of high-quality carbon and graphite products to nume­rous global custo­mers in a wide range of indus­tries, inclu­ding steel, auto­mo­bi­les, semi­con­duc­tors and elec­tro­nic compon­ents. Tokai Carbon has deve­lo­ped and deli­vered cutting-edge carbon product exper­tise to meet custo­mer needs. Tokai Carbon main­ta­ins a global network of 42 sites in 10 count­ries in Asia, Europe and North America. The company had conso­li­da­ted sales of JPY231 billion and total assets of JPY317 billion for the year ended Decem­ber 31, 2018. Tokai Carbon is listed on the Tokyo Stock Exchange.For more infor­ma­tion: www.tokaicarbon.co.jp/en/

About Triton
Since its foun­ding in 1997, Triton has laun­ched nine funds and focu­sed on compa­nies in the indus­trial, services, consu­mer goods and health­care sectors. The Triton funds invest in medium-sized compa­nies based in Europe and support their posi­tive development.Triton’s goal is to successfully deve­lop its port­fo­lio compa­nies over the long term by working in part­ner­ship. Triton and its manage­ment strive to gene­rate posi­tive change and growth through the sustainable impro­ve­ment of opera­tio­nal proces­ses and struc­tures. At present, Triton’s port­fo­lio includes 37 compa­nies with total sales of around EUR 14.6 billion and around 72,400 employees.

Munich/Stuttgart — Toge­ther with all other share­hol­ders, Gimv is selling its shares in the Stutt­gart-based soft­ware company thinkstep AG (www.thinkstep.com). The buyer is the US soft­ware service provi­der Sphera Solu­ti­ons. Thanks to the sustained support of all share­hol­ders, thinkstep has recor­ded a very posi­tive deve­lo­p­ment and was able to successfully convert the busi­ness model to a soft­ware-as-a-service (SaaS) solution.

The globally active company, head­quar­te­red in Lein­fel­den-Echter­din­gen near Stutt­gart, was foun­ded in 1991 and offers soft­ware and consul­ting services that help compa­nies manage sustaina­bi­lity and reduce their envi­ron­men­tal foot­print. Over the last few years, thinkstep has been able to steadily expand its impres­sive custo­mer base and today serves over 2,000 custo­mers from 20 indus­tries, inclu­ding in parti­cu­lar a large number of leading “Fortune 500” compa­nies from Germany and around the world.

thinkstep AG opera­tes in three busi­ness units: In the Corpo­rate Sustaina­bi­lity divi­sion, sustaina­bi­lity proces­ses are intro­du­ced and imple­men­ted. These include, for exam­ple, Group-wide energy manage­ment, corpo­rate social respon­si­bi­lity manage­ment and active resource opti­miza­tion. In the area of product sustaina­bi­lity, envi­ron­men­tal aspects are alre­ady taken into account in the deve­lo­p­ment phase and thus inte­gra­ted into subse­quent product manage­ment and manu­fac­tu­ring proces­ses. With the help of thinkstep’s product compli­ance solu­tion, compli­ance and repu­ta­tion risks can be iden­ti­fied and redu­ced at an early stage.

Gimv joined thinkstep in 2010 with a mino­rity stake toge­ther with Next47 with the aim of support­ing the company with capi­tal, know-how and network in its global expan­sion, opera­tio­nal streng­thening and simul­ta­neous trans­for­ma­tion from a licen­sing to a SaaS model. In the course of this, Gimv and Next47 gradu­ally increased their joint commit­ment, while at the same time some of the foun­ders remained on board with mino­rity stakes. In this way, thinkstep has grown into a leading global soft­ware provi­der in the field of Enter­prise Sustaina­bi­lity and Compli­ance Solu­ti­ons. With the sale and the plan­ned subse­quent inte­gra­tion into Sphera, the next step in the successful deve­lo­p­ment of the company is now being taken.

Dr. Sven Oleow­nik (photo), Part­ner and Head of Germany at Gimv, says: “thinkstep has under­gone a remar­kable trans­for­ma­tion in recent years and funda­men­tally reshaped its busi­ness model. Buil­ding on a very loyal custo­mer base, it has simul­ta­neously been able to further advance its global opera­ti­ons and tech­no­lo­gi­cal base. With inves­tors and consu­mers placing incre­asing importance on compa­nies opera­ting ethi­cally and envi­ron­men­tally consciously, the market for sustaina­bi­lity solu­ti­ons is highly attrac­tive and growing stron­gly. thinkstep is ideally posi­tio­ned for the future to further expand its market leader­ship now under a new flag.”

Lisa Henge­rer, Asso­ciate at Gimv in Munich and respon­si­ble for the Smart Indus­tries plat­form, adds: “thinkstep is another success story within our Smart Indus­tries soft­ware divi­sion. The sale to Sphera Solu­ti­ons is once again an excel­lent exam­ple of our ambi­tion to accom­pany our port­fo­lio compa­nies in their stra­te­gic deve­lo­p­ment and growth to become attrac­tive for an inter­na­tio­nally renow­ned indus­trial company like Sphera.”

The tran­sac­tion has no mate­rial impact on the net asset value of Gimv as of March 31, 2019. The tran­sac­tion is subject to custo­mary condi­ti­ons, inclu­ding appr­oval by the compe­ti­tion autho­ri­ties. Further finan­cial details will not be disclosed.

About Gimv
Gimv is a Euro­pean invest­ment company with almost 40 years of expe­ri­ence in private equity. The company is listed on Euron­ext Brussels, curr­ently mana­ges around EUR 1.1 billion and curr­ently invests in 55 port­fo­lio compa­nies, which toge­ther realize a turno­ver of more than EUR 2.75 billion and employ 14,000 people.

Gimv iden­ti­fies inno­va­tive, leading compa­nies with high growth poten­tial and supports them on their way to market leader­ship. Each of the four invest­ment plat­forms Connec­ted Consu­mer, Health & Care, Smart Indus­tries and Sustainable Cities is mana­ged by a dedi­ca­ted and compe­tent team, each based in Gimv’s home markets — Bene­lux, France and DACH — and supported by an exten­sive inter­na­tio­nal network of experts.

Milan/Düsseldorf/London — Ambi­enta SGR SpA, one of the largest sustaina­bi­lity-focu­sed private equity inves­tors in Europe, announ­ces that its port­fo­lio company Aroma­ta­Group SRL (“Aromata”) has comple­ted the 100% acqui­si­tion of Indus­trie Prodotti Alimen­tari Manenti (“IPAM”), a market leader in the produc­tion and distri­bu­tion of ingre­di­ents for the food industry.

The flavor and colo­rants market is worth over €12 billion and is expec­ted to grow at an annual rate of 3–4% over the next five years, under­pin­ned by long-term sustainable growth drivers. Ambi­enta reco­gni­zed the growth poten­tial of natu­ral food ingre­di­ents. Natu­ral raw mate­ri­als repre­sent the stron­gest growth driver in the food indus­try, with global growth of 7% versus zero growth for synthe­tic products. Substi­tu­tion of synthe­tic chemi­cals (from oil or inor­ga­nic chemi­cals) in flavor or colo­rant recipes with natu­ral ingre­di­ents that are orga­nic and pose no health risks is incre­asingly prefer­red by food manu­fac­tu­r­ers and consumers.

As a leading manu­fac­tu­rer of natu­ral flavors and colors for the food indus­try, Aromata is well posi­tio­ned to support the shift to natu­ral, healt­hier foods. Aromata has three produc­tion faci­li­ties in nort­hern Italy and serves over 1,200 custo­mers in 50 count­ries. In 2018, the Group gene­ra­ted appro­xi­m­ately 30 million euros in sales, 5 million euros in EBITDA and contri­bu­ted to avoi­ding 83 tons of pollut­ants. After a successful 2018, Aromata conti­nues to invest to expand its product and appli­ca­tion port­fo­lio: the acqui­si­tion of IPAM marks Aromata’s expan­sion into the adja­cent savory ingre­di­ents market.

IPAM is the Italian leader in the produc­tion and distri­bu­tion of high quality and func­tional ingre­di­ents for the food indus­try, such as bread­crumbs and dough mixes, mari­na­des and flavors. IPAM is based in Zibello Pole­sine, in the heart of the Italian “Food Valley”, and supplies over 300 custo­mers from two produc­tion sites.

The acqui­si­tion of IPAM will enable Aromata to gain a foot­hold in the large and attrac­tive ’savory’ ingre­di­ent market, offer new custo­mers a more exten­sive range of natu­ral flavors and colors, and jointly deve­lop both compa­nies’ natu­ral ingre­di­ent offe­rings. The tran­sac­tion provi­des Aromata with further expan­sion in the ingre­di­ents market to meet incre­asing custo­mer demand.

Hans Udo Wenzel, Presi­dent of Aroma­ta­Group, says: “The acqui­si­tion of IPAM is the first step in Aromata’s stra­te­gic expan­sion plan, enab­ling Aromata to broa­den its product range and streng­then its main compe­ti­tive advan­tage, which is to offer a full range of products to its customers.”

Euge­nio Manenti, foun­der and CEO of IPAM, added, “We are very plea­sed to join Aromata’s buy-and-build project and further expand the group’s leader­ship in natu­ral ingredients.”

Mauro Roversi (photo), Part­ner & Chief Invest­ment Offi­cer at Ambi­enta, commen­ted, “Stra­te­gic acqui­si­ti­ons are key to the growth of our port­fo­lio compa­nies. We welcome the IPAM team to Aromata and look forward to further growing our joint business.”

About Ambi­enta
Ambi­enta is a leading Euro­pean private equity fund based in Milan, Düssel­dorf and London. The focus is on growth invest­ments in indus­trial compa­nies that focus on sustaina­bi­lity trends. With over €1 billion in funds under manage­ment, the world’s largest pool of capi­tal for this stra­tegy, Ambi­enta has made 32 resource effi­ci­ency and envi­ron­men­tal invest­ments across Europe to date. Ambi­enta actively parti­ci­pa­tes in the deve­lo­p­ment of its port­fo­lio compa­nies, provi­ding indus­try and manage­ment exper­tise and global connec­ti­vity. www.ambientasgr.com.

Munich — PARAGON PARTNERS, one of the leading invest­ment compa­nies in the German-spea­king region, recently closed its PARAGON FUND III (“P3”) with capi­tal commit­ments of EUR 783 million. Due to strong demand, P3 signi­fi­cantly excee­ded both the origi­nal target size and the size of the prede­ces­sor fund, which closed at EUR 412 million.

The new fund was over­sub­scri­bed and gene­ra­ted strong demand mainly from exis­ting inves­tors, but also from some new ones. This helps PARAGON PARTNERS to broa­den its inves­tor base and further deve­lop its rela­ti­onships in Europe and North America. Euro­pean inves­tors, and espe­ci­ally inves­tors from German-spea­king count­ries, conti­nue to be well repre­sen­ted. The inves­tor base includes renow­ned insti­tu­tio­nal inves­tors such as funds of funds, public and company pension funds, insu­rance compa­nies, foun­da­ti­ons and family holding companies.

With the new fund, PARAGON PARTNERS can further expand its posi­tion as one of the leading invest­ment compa­nies in the German-spea­king region with a focus on sustainable value-orien­ted invest­ments in the range of EUR 30 million to EUR 250 million.

PARAGON PARTNERS is also plea­sed to announce the first invest­ment of the new fund: pro optik, the third largest opti­cian chain in Germany. The chain curr­ently compri­ses a network of 145 stores based on a successful part­ner­ship model, offe­ring its part­ners the oppor­tu­nity to act as either joint venture or fran­chise part­ners. pro optik sells around 400,000 pairs of glas­ses a year and the product range extends from high-quality frames from both well-known top brands and less expen­sive own brands to high-quality lenses and glas­ses. The company has also recently expan­ded its offe­ring to include hearing aids. In 2018, pro optik gene­ra­ted sales of EUR 125 million.

PARAGON PARTNERS conti­nues its proven invest­ment stra­tegy of inves­t­ing in estab­lished medium-sized compa­nies with opera­tio­nal growth and value enhance­ment poten­tial in Germany, Austria and Switz­er­land, as well as selec­tively in neigh­bor­ing count­ries. The invest­ment company is commit­ted to a sustainable invest­ment approach and inte­gra­tes envi­ron­men­tal, social and honest corpo­rate gover­nance conside­ra­ti­ons into its invest­ment decis­i­ons and also trans­fers these sustaina­bi­lity stan­dards into the corpo­rate gover­nance of its port­fo­lio companies.

The Munich-based fund is advi­sed by a moti­va­ted team of invest­ment mana­gers with many years of invest­ment and exten­sive opera­tio­nal expe­ri­ence, charac­te­ri­zed by strong cohe­sion and stabi­lity for more than 15 years.

About PARAGON PARTNERS
PARAGON PARTNERS is a private equity company foun­ded in 2004 with more than EUR 1.2 billion in equity under manage­ment. PARAGON PARTNERS works with its port­fo­lio compa­nies to achieve sustainable growth, opera­tio­nal excel­lence and market leader­ship. PARAGON PARTNERS unlocks new value in funda­men­tally attrac­tive busi­nesses and has the ability to address comple­xity from both a tran­sac­tional and opera­tio­nal perspec­tive and to repo­si­tion busi­nesses through custo­mi­zed value crea­tion programs.

Antwerp (BE) / Munich — Gimv, Sofin­nova and Gilde Health­care sell their shares in the biophar­maceu­ti­cal company Breath Thera­peu­tics. The company, which specia­li­zes in the deve­lo­p­ment of first-in-class inha­la­tion solu­ti­ons for severe lung dise­a­ses, raised appro­xi­m­ately €43.5 million in 2017 in one of the largest Euro­pean Series A rounds to date. With the support of the inves­tors, two global Phase III studies on inha­la­tion therapy solu­ti­ons for the rare lung dise­ase Bron­chio­li­tis Obli­terans Syndrome (BOS) have now been initia­ted. There is curr­ently no appro­ved therapy for BOS and the dise­ase is fatal in many cases. The buyer of Breath Thera­peu­tics is the Italian family-owned phar­maceu­ti­cal and chemi­cal company Zambon.

Gimv joined Sofin­nova Part­ners (France) as lead inves­tor in Breath Thera­peu­tics in March 2017. Other inves­tors were Gilde Health­care (Nether­lands) and PARI Pharma as licen­sor for the inha­la­tion devices. In addi­tion to the finan­cial support, Gimv’s exper­tise was also crucial to the success of the spin-out process, to the syndi­ca­tion of the finan­cing struc­ture, to the imple­men­ta­tion of the stra­tegy, and to the imple­men­ta­tion of lean, inter­nal proces­ses. Thanks to this exter­nal know-how, Breath Thera­peu­tics has been able to further deve­lop its own inno­va­tion capa­bi­li­ties into a mature therapy solu­tion, as well as to build up a top-class team of experts in Europe and the USA.

Dr. Karl Nägler, Part­ner and respon­si­ble for the Health & Care plat­form at Gimv Germany, says: “We are even more plea­sed with the successful deve­lo­p­ment of the company over the past two years, as Gimv was signi­fi­cantly invol­ved in the stra­te­gic direc­tion and setting up of the plat­form for growth from the very begin­ning. The poten­tial of Breath Thera­peu­tics and the compound was clear to us at an early stage, as lung dise­a­ses are unfort­u­na­tely on the rise — espe­ci­ally due to envi­ron­men­tal factors and chan­ging life­styles. Against this back­ground, with Zambon’s support, Breath Thera­peu­tics is in an excel­lent posi­tion to successfully commer­cia­lize the product in the future and to deve­lop new fields of application.”

Dr. Jens Stege­mann, Chief Execu­tive Offi­cer at Breath Thera­peu­tics, adds: “With this compound, Breath Thera­peu­tics has deve­lo­ped a product that can signi­fi­cantly improve the lives of many people. We have found a part­ner that shares our vision in Zambon, an inno­va­tive company with high ethi­cal stan­dards and a clear focus on pati­ent well-being. Alre­ady, we have advan­ced the deve­lo­p­ment of a poten­tial first-in-class therapy for BOS, initia­ted two global Phase III trials, and are thus excel­lently posi­tio­ned in the market. Thanks to Zambon’s infra­struc­ture, exper­tise and clear focus on rese­arch and deve­lo­p­ment, we can acce­le­rate these proces­ses even further and make the treat­ment available to as many people as possi­ble as quickly as possi­ble. We would like to thank our former part­ners Gimv, Sofin­nova and Gilde Health­care for their support, which was crucial to the successful deve­lo­p­ment of our company, espe­ci­ally in the early years.”

This tran­sac­tion increa­ses Gimv’s NAV by EUR 20 million (as of March 31, 2019). With this invest­ment, Gimv achie­ved an ROI above its stated long-term target of 15%.

About Gimv
Gimv is a Euro­pean invest­ment company with almost 40 years of expe­ri­ence in private equity. The company is listed on Euron­ext Brussels, curr­ently mana­ges around EUR 1.1 billion and curr­ently invests in 55 port­fo­lio compa­nies, which toge­ther realize a turno­ver of more than EUR 2.75 billion and employ 14,000 people.

Gimv iden­ti­fies inno­va­tive, leading compa­nies with high growth poten­tial and supports them on their way to market leader­ship. Each of the four invest­ment plat­forms Connec­ted Consu­mer, Health & Care, Smart Indus­tries and Sustainable Cities is mana­ged by a dedi­ca­ted and compe­tent team, each based in Gimv’s home markets — Bene­lux, France and DACH — and supported by an exten­sive inter­na­tio­nal network of experts.

Munich/Amsterdam/Oirschot — Equis­tone Part­ners Europe (“Equis­tone”), one of Europe’s leading equity inves­tors, is acqui­ring Heras (“Heras”). The seller is the British buil­ding mate­ri­als manu­fac­tu­rer CRH Plc. Heras is a leading provi­der of property protec­tion solu­ti­ons head­quar­te­red in Oirschot, the Nether­lands. The Heras manage­ment team has a mino­rity stake. Gilles Rabot, with Heras since 2015, will conti­nue to lead the company. The parties have agreed not to disc­lose details of the tran­sac­tion. The sale is still subject to appr­oval by the rele­vant anti­trust authorities.

Heras was foun­ded in 1952 and offers a wide port­fo­lio of mobile and perma­nent property protec­tion systems and products. It includes fencing systems, manu­ally opera­ted and auto­ma­tic gates, vehicle barriers and elec­tro­nic surveil­lance systems. The company has a strong presence in Europe, with sales offices in the Nether­lands, the United King­dom, Sweden, Norway, Germany and France. Produc­tion faci­li­ties are loca­ted in the Nether­lands, Belgium, France, Sweden and the United King­dom. Heras employs over 1,100 people and has annual sales of over 220 million euros.

Heras’ perma­nent medium and high-secu­rity property protec­tion solu­ti­ons are used in a wide variety of fields, such as border control and the protec­tion of mili­tary instal­la­ti­ons or criti­cal infra­struc­ture, as well as schools and children’s play­grounds. All Heras solu­ti­ons can be tail­o­red to speci­fic custo­mer needs. The company also offers a range of addi­tio­nal services, such as instal­la­tion, system inte­gra­tion, commis­sio­ning, and main­ten­ance and repair. Heras mobile property protec­tion solu­ti­ons are mainly used for secu­ring cons­truc­tion sites and large events. Custo­mers in this area include cons­truc­tion compa­nies, govern­ment agen­cies, event orga­ni­zers, rental compa­nies, distri­bu­tors, whole­sa­lers and instal­la­tion companies.

Follo­wing the carve-out from CRH Plc, Heras intends to drive conso­li­da­tion in a highly frag­men­ted market through targe­ted acqui­si­ti­ons with its new part­ner Equis­tone. Addi­tio­nal orga­nic growth is to be achie­ved by deve­lo­ping new products and services, estab­li­shing further custo­mer rela­ti­onships and expan­ding exis­ting networks.

Hubert van Wolfs­win­kel (photo), Direc­tor at Equis­tone, says: “Heras has impres­sed us very much. The company owes its leading market posi­tion, among other things, to a strong network of produc­tion sites in Europe, long-stan­ding custo­mer rela­ti­onships and expe­ri­en­ced manage­ment.” Dirk Sche­kerka, Senior Part­ner at Equis­tone, added: “Heras has an excel­lent team of employees and mana­gers. We now look forward to working with the company as it conti­nues to grow and expand into new markets.”

Gilles Rabot, Mana­ging Direc­tor at Heras, says: “With Equis­tone, we have gained a relia­ble and finan­ci­ally strong new part­ner. With Equistone’s support, we intend to main­tain our growth trajec­tory and further expand our market posi­tion. We will conti­nue to deve­lop and offer a world-class and inno­va­tive range of mobile and perma­nent property protec­tion solu­ti­ons to meet the conti­nuously incre­asing secu­rity needs of the market.”

On the Equis­tone side, Dirk Sche­kerka, Hubert van Wolfs­win­kel and Moritz Treude are respon­si­ble for the tran­sac­tion. The inves­tor was advi­sed by Munich Stra­tegy (Commer­cial), EY (Finan­cial, IT, Opera­ti­ons & Tax), Clif­ford Chance (Legal), ERM (Envi­ron­men­tal, Health & Safety) and Houli­han Lokey (M&A, Financing).

About Equis­tone Part­ners Europe
Equis­tone Part­ners Europe is one of Europe’s leading equity inves­tors with a team of more than 40 invest­ment specia­lists in six offices in Germany, Switz­er­land, the Nether­lands, France and the UK. Equis­tone prima­rily invests in estab­lished medium-sized compa­nies with a good market posi­tion, above-average growth poten­tial and an enter­prise value of between EUR 50 and 500 million. Since its foun­ding, equity has been inves­ted in more than 140 tran­sac­tions, mainly mid-market buy-outs. The port­fo­lio curr­ently compri­ses over 40 compa­nies across Europe, inclu­ding around 20 active holdings in Germany, Switz­er­land and the Nether­lands. Equis­tone is curr­ently inves­t­ing from its sixth fund, which closed in March 2018 with €2.8 billion at the hard cap.

About Heras
Since 1952 and with its roots in the Nether­lands, Heras has evol­ved from a fencing specia­list to a full-service peri­me­ter protec­tion solu­ti­ons provi­der opera­ting in six count­ries. The Group curr­ently employs more than 1,100 highly quali­fied specialists.
Toge­ther, we design, manu­fac­ture, install and main­tain peri­me­ter protec­tion solu­ti­ons for busi­ness, commu­nity and industry.

Guernsey/ Munich/ Amsterdam/ Rijs­wijk — The invest­ment fund Perusa Part­ners Fund 2, L.P. (“Perusa”), advi­sed by the inde­pen­dent Perusa GmbH, has sold Xindao Inter­na­tio­nal GmbH and its subsi­dia­ries (“Xindao”) to Gilde Buy-Out Fund V (“Gilde”). The parties have agreed not to disc­lose the purchase price or the details of the transaction.

Perusa acqui­red Xindao Holding BV from its foun­ders in August 2017. Foun­ded in 1986, Xindao is a leading supplier of high-quality func­tional promo­tio­nal products to more than 4,500 B2B and B2C retail­ers throug­hout Europe and the world. The company has an excel­lent repu­ta­tion as a premium supplier that gene­ra­tes a large part of its sales with self-desi­gned bran­ded products. In addi­tion to its head­quar­ters in Rijs­wijk, the Nether­lands, Xindao opera­tes its own prin­ting and logi­stics center in Roma­nia and a design studio and procu­re­ment center in Shang­hai. The company sells its products through a network of its own sales compa­nies in Germany, France, the Nether­lands, Spain, Sweden, the UK, China and the USA, as well as through exclu­sive repre­sen­ta­ti­ves in Russia and Italy.

Successful trans­for­ma­tion to a manage­ment-led company
Xindao has a history of double-digit annual growth. As a result, the company has more than tripled its sales in the last ten years. Under Perusa’s owner­ship, Xindao comple­ted its trans­for­ma­tion into a company led by inde­pen­dent manage­ment, expan­ded its inter­na­tio­nal reach through the acqui­si­ti­ons of Xindao UK and Xindao Spain, and estab­lished XD Design as an emer­ging luggage and back­pack brand in global retail.

“Under Perusa, we have succee­ded in further streng­thening our posi­tion as one of the largest suppli­ers in the promo­tio­nal products indus­try in Europe. We have worked extre­mely successfully with Perusa. This is a good exam­ple of how a private equity firm and a form­erly owner-mana­ged company can work toge­ther to drive the growth of a busi­ness,” said Albert van der Veen, CEO of Xindao Group.

“The company has succee­ded in conti­nuing to follow an excel­lent econo­mic path during the tran­si­tion from an owner-mana­ged to a manage­ment-mana­ged company , ” sums up Dr. Hanno Schmidt-Gothan, Mana­ging Direc­tor of the consul­ting Perusa GmbH. “Xindao demons­tra­tes the importance of a strong manage­ment team for the company’s deve­lo­p­ment, which has estab­lished highly effi­ci­ent struc­tures and proces­ses as well as an excel­lent working envi­ron­ment,” adds Raphael Weller, Invest­ment Direc­tor of the advi­sing Perusa GmbH.

About Perusa
Perusa is an inde­pen­dent equity invest­ment company that curr­ently invests 350 million euros of equity in medium-sized compa­nies and group busi­nesses from German-spea­king or Scan­di­na­vian count­ries via two funds. Perusa takes a highly opera­tio­nal approach to streng­thening perfor­mance and thus lever­aging the long-term value crea­tion poten­tial of its port­fo­lio compa­nies. Further­more, stra­te­gic acqui­si­ti­ons (buy-and-build stra­tegy) are targe­ted to streng­then the growth of the port­fo­lio compa­nies. The funds are advi­sed by Perusa GmbH.

Frank­furt a. M./ Munich/ Boston — Inter­na­tio­nal law firm Weil, Gotshal & Manges LLP have advi­sed Sili­con Valley-based finan­cial inves­tor TCV on the acqui­si­tion of shares in Flix­Mo­bi­lity GmbH. The Series F finan­cing round was led by TCV toge­ther with finan­cial inves­tor Perm­ira. Exis­ting inves­tor HV Holtz­brinck Ventures was also invol­ved in the current sixth round, which repres­ents the largest capi­tal injec­tion in an invest­ment round for a German start-up to date.

Munich-based Flix­Mo­bi­lity GmbH, argu­ably the best-known unicorn among German start-ups, is the parent company of the global mobi­lity plat­forms Flix­Bus and Flix­Train. The new capi­tal will be used for global expan­sion, parti­cu­larly in the USA, South America and Asia.

The Weil team was led by Frank­furt-based Corpo­rate Part­ner Dr. Chris­tian Tapp­ei­nerin this tran­sac­tion. and compri­sed the part­ners Dr. Hendrik Röhricht (Corpo­rate, Frank­furt), Tobias Geer­ling (Tax, Munich), Kevin Sulli­van (Corpo­rate, Boston) and the asso­cia­tes Konrad v. Buch­waldt, Julian Schwa­ne­beck, Sebas­tian Bren­ner, Simon Stei­ner, Sara Afschar-Hamdi (all Corpo­rate, Frank­furt), Andreas Fogel, Marcel Ander­sen, Caro­lin Ober­maier (all Corpo­rate Munich), Mareike Pfeif­fer (Labor Law, Frank­furt), Aurel Hille (Anti­trust, Frank­furt), Marcus Kaiser (IP, Frank­furt), Nico­las Bech­told (Liti­ga­tion, Frank­furt) as well as Para­le­gal Kris­tina Thiel (Labor Law, Frankfurt).

Berlin/Eschenburg/Düsseldorf — MEDIAN, a port­fo­lio company of the invest­ment firm Water­land Private Equity and the largest private opera­tor of reha­bi­li­ta­tion clinics in Germany, signed two take­over agree­ments on July 18, thus conti­nuing its buy & build acti­vi­ties. With the Eschen­burg Clinic and the Düssel­dorf Rhein-Reha, MEDIAN is further expan­ding its leading posi­tion in the reha­bi­li­ta­tion market. The parties have agreed not to disc­lose the purchase price or further finan­cial details of both transactions.

In the Lahn-Dill district of central Hesse, MEDIAN takes over the Eschen­burg Clinic. It comple­ments the range of services in the core area of addic­tion and depen­dency disor­ders. It offers 87 treat­ment beds and a wide range of treat­ment for drug and alco­hol addic­tion. A special compe­tence of the Eschen­burg Clinic is the treat­ment of addic­tion problems of elderly people. The clinic also includes three outpa­ti­ent faci­li­ties in Dillen­burg, Wetz­lar and Gies­sen. Through this acqui­si­tion, MEDIAN is not only expan­ding its status as the largest private reha­bi­li­ta­tion company in Germany. With a total of 30 specia­list clinics and adapt­a­tion houses nati­on­wide, MEDIAN is now also the market leader in the field of reha­bi­li­ta­tion for addic­tion and depen­dency disor­ders. MEDIAN is also conti­nuing its growth course in nort­hern Rhine­land-Pala­ti­nate and Hesse. In Janu­ary 2019, the health­care company had alre­ady acqui­red Klini­ken Wied GmbH & Co. KG in the Wester­wald region, 65 kilo­me­ters away. Both faci­li­ties have a simi­lar perfor­mance profile and are to coope­rate closely in the future.

In Düssel­dorf, MEDIAN will take over the Outpa­ti­ent Cardio­logy Rehab Center Rhein-Reha, the take­over will be comple­ted at the turn of the year 2019/20. Rhein-Reha will be inte­gra­ted with its entire clinic opera­ti­ons and also by name under the umbrella of MEDIAN’s alre­ady exis­ting Outpa­ti­ent Health Center Düssel­dorf. The tran­si­tion will be desi­gned for all pati­ents and employees without inter­rupt­ing ongo­ing treatments.

Dr. Cars­ten Rahlfs (photo), Mana­ging Part­ner of Water­land, says: “The demand for rehab services for the treat­ment of addic­tion and depen­dency disor­ders is growing steadily. MEDIAN, as the new number one in this specia­list area, will bene­fit from the exper­tise of Klinik Eschen­burg. This is because the faci­lity enjoys an excel­lent repu­ta­tion and ideally comple­ments MEDIAN’s presence in the region. In addi­tion, we are plea­sed about the expan­sion of the range of services in cardio­logy through the acqui­si­tion of the Düssel­dorf Rhein-Reha. The center’s clout will be fully deve­lo­ped after the inte­gra­tion has been comple­ted at the begin­ning of next year.”

Since Waterland’s entry as a share­hol­der, MEDIAN has now taken over 21 indi­vi­dual clinics and clinic groups and inte­gra­ted them into the group of compa­nies. In doing so, MEDIAN is aiming for quality leader­ship in medi­cal reha­bi­li­ta­tion and is inves­t­ing heavily in the expan­sion of therapy offe­rings, in addi­tio­nal staff, in the digi­ta­liza­tion of proces­ses and in the moder­niza­tion of clinic buil­dings. Toge­ther with the new faci­lity, the Group compri­ses around 120 clinics and faci­li­ties with 18,500 beds, trea­ting more than 230,000 pati­ents annu­ally. The health­care company, which employs around 15,000 people, includes reha­bi­li­ta­tion clinics as well as acute psych­ia­tric hospi­tals, therapy centers, outpa­ti­ent clinics and reinte­gra­tion faci­li­ties in 13 German states. The company thus offers nati­on­wide coverage of so-called after­care and parti­ci­pa­tion services in all specia­list areas.

With Waterland’s support, MEDIAN plans to further conso­li­date the German reha­bi­li­ta­tion market — both in terms of expan­ding its regio­nal presence and in addi­tio­nal medi­cal special­ties. In addi­tion, MEDIAN aims to further inte­grate pati­ent pathways and to imple­ment evidence-based medi­cine even more stron­gly in its therapy offerings.

As a share­hol­der in MEDIAN, the inde­pen­dent invest­ment company Water­land Private Equity has exten­sive expe­ri­ence in the health­care sector. In addi­tion to MEDIAN, the port­fo­lio in Germany includes, for exam­ple, ATOS, a group of soma­tic acute-care clinics specia­li­zing in cutting-edge ortho­pe­dic medi­cine, and the care service provi­der Schö­nes Leben Group, a service plat­form for outpa­ti­ent, inpa­ti­ent, and open geria­tric care as well as mobile services, assis­ted living, and leisure acti­vi­ties. Water­land also holds a signi­fi­cant stake in Hanse­fit, a leading network asso­cia­tion for company sports and health services with more than 1,400 affi­lia­ted fitness studios. Waterland’s port­fo­lio of compa­nies in the health­care sector was joined at the begin­ning of the year by Reha­con, where the inves­tor has alre­ady supported four acqui­si­ti­ons. Today, Reha­con is one of the leading provi­ders of physio­the­rapy services and therapy offe­rings in Europe. Nati­on­wide, the company opera­tes more than 120 therapy centers and employs over 800 people.

About Water­land
Water­land is an inde­pen­dent private equity invest­ment firm that helps compa­nies realize their growth plans. With substan­tial finan­cial support and indus­try exper­tise, Water­land enables its port­fo­lio compa­nies to achieve acce­le­ra­ted growth both orga­ni­cally and through acqui­si­ti­ons. Water­land has offices in the Nether­lands (Bussum), Belgium (Antwerp), Germany (Hamburg, Munich), Poland (Warsaw), the UK (Manches­ter), Denmark (Copen­ha­gen) and Switz­er­land (Zurich). Curr­ently, six billion euros in equity funds are under management.